Condition: Indolent B-Cell Non-Hodgkin Lymphoma · Sponsor: BioInvent International AB
Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab with or without Acalabrutinib in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That has Relapsed or is Refractory to Rituximab
This description comes directly from the study's public registry record.
Erika Bågeman · +46706126618 · erika.bageman@bioinvent.com
Andres McAllister, MD, PhD · andres.mcallister@bioinvent.com
Always discuss trial participation with your own doctor first.
| Emory University Hospital | Atlanta, Georgia, United States | Active Not Recruiting |
| Norton Cancer Institute - St. Matthews 3991 Dutchmans Lane Medical Plaza II, Suite 405 | Louisville, Kentucky, United States | Recruiting |
| Hospital São Rafael | Salvador, Estado de Bahia, Brazil | Recruiting |
| Hospital de Clínicas de Porto Alegre | Porto Alegre, Rio Grande do Sul, Brazil | Recruiting |
| Hospital Erasto Gaertner - Liga Paranaense de Combate ao Câncer | Curitiba, Brazil | Not Yet Recruiting |
| Ruschel Medicina e Pesquisa Clínica | Rio de Janeiro, Brazil | Not Yet Recruiting |
| A.C. Camargo Cancer Center | São Paulo, Brazil | Recruiting |
| Hospital Amaral Carvalho | São Paulo, Brazil | Not Yet Recruiting |
| Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo | São Paulo, Brazil | Not Yet Recruiting |
| Hospital Israelita Albert Einstein | São Paulo, Brazil | Recruiting |
| Hospital Samaritano | São Paulo, Brazil | Not Yet Recruiting |
| Hospital Sírio-Libanês | São Paulo, Brazil | Not Yet Recruiting |
+ 15 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03571568